Proteome Sciences (AIM:PRM), the AIM-listed proteomics services company, has won a clinical contract tied to its target engagement and chemoproteomics platform, with the work expected to precede a new clinical trial programme due to launch later in 2026.
The company described the contract as "significant" and positioned it as a precursor engagement, suggesting a deeper commercial relationship may follow if the trial programme proceeds as anticipated.
No financial terms were disclosed.
